Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spero Therapeutics announces antibiotics collaboration with Roche
Founded in April 2013 by Dr Ankit Mahadevia in collaboration with the Partners Innovation Fund, Spero Therapeutics is supported by the Atlas Venture seed program. Atlas Venture, SR
Founded in April 2013 by Dr Ankit Mahadevia in collaboration with the Partners Innovation Fund, Spero Therapeutics is supported by the Atlas Venture seed program. Atlas Venture, SR
The initiation follows completion of the first treatment cycle in the three patients enrolled in the seventh dose level cohort, in which L-DOS47 therapy was well tolerated as
APIC produces active pharmaceutical ingredients (APIs), intermediates and investigational new drugs, along with fine chemicals and reagents. The new manufacturing facility, located in a Neuland complex in Pashamylaram,
As part of the deal, DKSH will provide marketing, sales, warehousing, physical distribution, credit management and collection services for BMS in certain markets. DKSH offers a tailor-made, integrated
Additionally, the company has earned a $15m milestone payment from Roche related to the initiation of the randomized, double-blind, placebo-controlled, single ascending dose trial. The trial is designed
German pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both
The FDA acceptance enables Stemline Therapeutics to advance SL-701 into a Phase II trial of adults with glioblastoma multiforme (GBM) in first recurrence. SL-701, a subcutaneously-administered cancer vaccine,
Mersana’s conjugation technology includes its biodegradable Fleximer polymer and a broad array of customizable linker chemistries matched to its diverse, cytotoxic payloads. As part of the deal, Takeda
The company has started the launch preparation with its US distributor partner and will commence marketing the product as soon as the launch preparation is completed. According to
Aptiom, a voltage-gated sodium channel blocker, is a new chemical entity approved by the US Food and Drug Administration (FDA) in November 2013, and is available in four